GREGORY L. BRADEN, M.D.; JOHN P. FITZGIBBONS, M.D.; MICHAEL J. GERMAIN, M.D.; HOWARD M. LEDEWITZ, M.D.
The pharmacokinetics of procainamide and its major metabolite, N-acetylprocainamide, are significantly altered in patients with chronic renal failure (1-4). Because N-acetylprocainamide is normally eliminated through renal excretion, it tends to accumulate in patients with renal failure and may reach toxic levels in patients on chronic dialysis despite adequate dialytic therapy (1-4). In addition, recent reports of N-acetylprocainamide intoxication in dialysis patients have shown that therapy either by peritoneal dialysis (5) or hemodialysis (6) is of questionable benefit. We report the case of a patient on chronic hemodialysis who developed N-acetylprocainamide intoxication and show the superiority of hemoperfusion over hemodialysis in
Learn more about subscription options.
Register Now for a free account.
BRADEN GL, FITZGIBBONS JP, GERMAIN MJ, LEDEWITZ HM. Hemoperfusion for Treatment of N-Acetylprocainamide Intoxication. Ann Intern Med. 1986;105:64–65. doi: 10.7326/0003-4819-105-1-64
Download citation file:
Published: Ann Intern Med. 1986;105(1):64-65.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only